Dendrogenix, an innovative biotechnology company based in Liège (Belgium) announced today positive results from its first Phase 1 clinical trial evaluating its drug candidate DX243. Building on these encouraging data, the company plans to initiate a Phase 2a clinical trial in the first quarter of 2026 in the field of…

Created in 2000 in the heart of Namur, the URBM is made up of 5 teams from UNamur and one from ULB. It employs 50 researchers and has privileged access to a BL3 platform. Its basic research activities will generate applications for therapeutic and vaccine purposes. The URBM focuses its…

The Institut de Pathologie et de Génétique is a non-profit association founded in Charleroi, Belgium in 1958. It has 350 highly specialized and dedicated staff. Each year it carries out more than 450,000 analyses. The IPG’s activity is based on 3 essential pillars: anatomic pathology, the molecular biology laboratory and the human genetics centre, one of 8 such centres in Belgium. A far-reaching expertise & thrilling outlook! 🧬